☰
×
News
Top 20
Insights
Insights+
ThoughtSpot
Interviews
Viewpoints
Exclusive
Spotlight
Events
Magazine
Bespoke
Newswire
x
Search
Search here
Search here
Subscribe Now
CHMP’s
AstraZeneca's Forxiga (dapagliflozin) Receives CHMP's Recommendation for Approval to Treat Chronic Kidney Disease in EU
June 28, 2021
Samsung Bioepis and Biogen Receive the CHMP's Positive Opinion Recommending Approval of Byooviz (biosimilar- ranibizumab) for Reti...
June 28, 2021
Novartis' Kisqali (ribociclib) (as a Combination Therapy) Receives CHMP's Expanded Label Recommendation for HR+/HER2- Locally Adva...
November 19, 2018
Load more...
Back to Home
Modal title
×
Modal body text goes here.
